Spots Global Cancer Trial Database for braf inhibitor
Every month we try and update this database with for braf inhibitor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors | NCT01231594 | Cancer | GSK2118436 GSK1120212 Other approved ... | 18 Years - | Novartis | |
| A Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects With V600 BRAF Mutation-Positive Tumors | NCT01738451 | Cancer | GSK2118436 75 m... Placebo | 18 Years - | GlaxoSmithKline | |
| Melanoma Metastasized to the Brain and Steroids | NCT03563729 | Malignant Melan... | Pembrolizumab I... Ipilimumab Inje... Nivolumab Injec... Encorafenib Binimetinib Dabrafenib Trametinib | 18 Years - | Herlev Hospital | |
| An Absorption, Distribution, Metabolism and Excretion (ADME) Study of Single Oral Dose [14C] GSK2118436 in Subjects With BRAF Mutant Solid Tumors | NCT01262963 | Cancer | GSK2118436 | 18 Years - | GlaxoSmithKline | |
| Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer | NCT01719380 | Colorectal Canc... | LGX818 Cetuximab BYL719 | 18 Years - | Pfizer | |
| An Absorption, Distribution, Metabolism and Excretion (ADME) Study of Single Oral Dose [14C] GSK2118436 in Subjects With BRAF Mutant Solid Tumors | NCT01262963 | Cancer | GSK2118436 | 18 Years - | GlaxoSmithKline | |
| A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors | NCT04913285 | Solid Tumor, Ad... Non-small Cell ... Melanoma | KIN-2787 KIN-2787 and bi... | 18 Years - | Pierre Fabre Medicament | |
| BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation | NCT01894672 | Melanoma | LGX818 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Association of Hydroxychloroquine, BRAF and MEK Inhibitors in Metastatic Melanoma : a Retrospective Case-control Study. | NCT04760080 | Dermatology and... | pre-treatment d... during study tr... | 18 Years - | Hospices Civils de Lyon | |
| Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors | NCT04249843 | Solid Tumor B-Raf Mutation-... | BGB-3245 | 18 Years - | MapKure, LLC | |
| BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation | NCT01894672 | Melanoma | LGX818 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib | NCT02382549 | Melanoma | BRAF inhibitor 6MHP MEK inhibitor | 18 Years - | University of Virginia | |
| A Phase I Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2118436 in Subjects With Solid Tumors | NCT00880321 | Cancer | GSK2118436 GSK2118436 Midazolam | 18 Years - | GlaxoSmithKline | |
| Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases | NCT03430947 | Malignant Melan... BRAF V600 Mutat... Brain Metastase... | Vemurafenib Cobimetinib | 18 Years - | Technische Universität Dresden | |
| Melanoma Metastasized to the Brain and Steroids | NCT03563729 | Malignant Melan... | Pembrolizumab I... Ipilimumab Inje... Nivolumab Injec... Encorafenib Binimetinib Dabrafenib Trametinib | 18 Years - | Herlev Hospital | |
| BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation | NCT01894672 | Melanoma | LGX818 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib | NCT02382549 | Melanoma | BRAF inhibitor 6MHP MEK inhibitor | 18 Years - | University of Virginia | |
| A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors | NCT01340846 | Cancer | Warfarin Ketoconazole Gemfibrozil GSK2118436 150m... GSK2118436 75mg | 18 Years - | GlaxoSmithKline | |
| BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia | NCT01711632 | Hairy Cell Leuk... | Vemurafenib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| An Open Label Study to Examine the Effects of a High-Fat Meal and Particle Size on the Pharmacokinetics of Orally Administered GSK2118436 in Subjects With BRAF Mutation Positive Tumor | NCT01231568 | Cancer | Regimen A Regimen B Regimen C Regimen D | 18 Years - | GlaxoSmithKline | |
| Melanoma Metastasized to the Brain and Steroids | NCT03563729 | Malignant Melan... | Pembrolizumab I... Ipilimumab Inje... Nivolumab Injec... Encorafenib Binimetinib Dabrafenib Trametinib | 18 Years - | Herlev Hospital | |
| Determination of the Absolute Bioavailability of GSK2118436 Following a Single Oral Dose Co-Administered With an Intravenous Radiolabelled Microtracer of GSK2118436 in Subjects With BRAF Mutant Solid Tumors | NCT01340833 | Cancer | GSK2118436 | 18 Years - | GlaxoSmithKline | |
| Determination of the Absolute Bioavailability of GSK2118436 Following a Single Oral Dose Co-Administered With an Intravenous Radiolabelled Microtracer of GSK2118436 in Subjects With BRAF Mutant Solid Tumors | NCT01340833 | Cancer | GSK2118436 | 18 Years - | GlaxoSmithKline | |
| An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer | NCT03915951 | Non-small Cell ... | encorafenib binimetinib | 18 Years - | Pfizer | |
| A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma to the Brain | NCT01266967 | Melanoma and Br... | GSK2118436 | 18 Years - | GlaxoSmithKline | |
| Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma | NCT01616199 | Advanced BRAF-m... | PX-866 vemurafenib | 18 Years - | Seagen Inc. | |
| BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC) | NCT01750918 | Cancer | Dabrafenib Trametinib Panitumumab 5-fluorouracil | 18 Years - | Novartis | |
| Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD). | NCT01682083 | Melanoma | Dabrafenib Trametinib Placebos | 18 Years - | Novartis | |
| Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212 | NCT01072175 | Cancer | GSK2118436 GSK1120212 | 18 Years - | Novartis | |
| Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites | NCT01978236 | Melanoma and Br... | Dabrafenib 150 ... Trametinib 2.0 ... | 18 Years - | GlaxoSmithKline | |
| Rechallenge of BRAF +/- MEK Inhibitors Following an Adverse Event in Patients With Cancer | NCT05080361 | Cancer | BRAF inhibitor | - | University Hospital, Caen | |
| Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer | NCT01719380 | Colorectal Canc... | LGX818 Cetuximab BYL719 | 18 Years - | Pfizer | |
| An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer | NCT03915951 | Non-small Cell ... | encorafenib binimetinib | 18 Years - | Pfizer | |
| Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases | NCT03430947 | Malignant Melan... BRAF V600 Mutat... Brain Metastase... | Vemurafenib Cobimetinib | 18 Years - | Technische Universität Dresden | |
| Rechallenge of BRAF +/- MEK Inhibitors Following an Adverse Event in Patients With Cancer | NCT05080361 | Cancer | BRAF inhibitor | - | University Hospital, Caen | |
| Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites | NCT01978236 | Melanoma and Br... | Dabrafenib 150 ... Trametinib 2.0 ... | 18 Years - | GlaxoSmithKline | |
| Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD). | NCT01682083 | Melanoma | Dabrafenib Trametinib Placebos | 18 Years - | Novartis | |
| BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation | NCT01894672 | Melanoma | LGX818 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor | NCT01037127 | Cancer | GSK1120212 | 18 Years - | GlaxoSmithKline |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
